[go: up one dir, main page]

ES2145007T3 - Determinacion de motivos peptidicos en moleculas del mhc. - Google Patents

Determinacion de motivos peptidicos en moleculas del mhc.

Info

Publication number
ES2145007T3
ES2145007T3 ES92909723T ES92909723T ES2145007T3 ES 2145007 T3 ES2145007 T3 ES 2145007T3 ES 92909723 T ES92909723 T ES 92909723T ES 92909723 T ES92909723 T ES 92909723T ES 2145007 T3 ES2145007 T3 ES 2145007T3
Authority
ES
Spain
Prior art keywords
reasons
mhc
determination
moleculas
peptidic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92909723T
Other languages
English (en)
Inventor
Hans-Georg Rammensee
Kirsten Falk
Olaf Roetzschke
Stefan Stevanovic
Guether Jung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19914116256 external-priority patent/DE4116256C2/de
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften
Application granted granted Critical
Publication of ES2145007T3 publication Critical patent/ES2145007T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

EL PRESENTE INVENTO CONCIERNE A UN PROCEDIMIENTO PARA LA DETERMINACION DE MOTIVOS ALELOESPECIFICOS DE PEPTIDOS SOBRE MOLECULAS DEL MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) DE LAS CLASES I Y II, ASI COMO DE LOS MOTIVOS DE PEPTIDOS QUE PUEDEN PREPARARSE MEDIANTE ESTE PROCEDIMIENTO. ADEMAS, SE DA A CONOCER LA UTILIZACION DE LOS MOTIVOS DE PEPTIDOS CONFORMES AL INVENTO PARA LA PREPARACION DE UN AGENTE DIAGNOSTICO O TERAPEUTICO.
ES92909723T 1991-05-17 1992-05-15 Determinacion de motivos peptidicos en moleculas del mhc. Expired - Lifetime ES2145007T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19914116256 DE4116256C2 (de) 1991-05-17 1991-05-17 Bestimmung von Peptidmotiven auf MHC-Molekülen

Publications (1)

Publication Number Publication Date
ES2145007T3 true ES2145007T3 (es) 2000-07-01

Family

ID=6431930

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92909723T Expired - Lifetime ES2145007T3 (es) 1991-05-17 1992-05-15 Determinacion de motivos peptidicos en moleculas del mhc.

Country Status (10)

Country Link
US (1) US5747269A (es)
EP (1) EP0584136B1 (es)
JP (2) JP3424752B2 (es)
AT (1) ATE189527T1 (es)
AU (1) AU1694392A (es)
CA (2) CA2471093A1 (es)
DE (2) DE4143467C2 (es)
DK (1) DK0584136T3 (es)
ES (1) ES2145007T3 (es)
WO (1) WO1992021033A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
SG52492A1 (en) * 1992-08-07 1998-09-28 Cytel Corp Hla binding peptides and their uses
DE4238416A1 (de) * 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen
DE4423392A1 (de) * 1994-07-04 1996-01-11 Birsner & Grob Biotech Gmbh Verfahren zur Identifizierung antigener Peptide
US6413517B1 (en) 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
US6379970B1 (en) * 1999-04-30 2002-04-30 The Arizona Board Of Regents On Behalf Of The University Of Arizona Analysis of differential protein expression
DE19925199A1 (de) * 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
WO2001021189A1 (en) * 1999-07-19 2001-03-29 Epimmune Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
WO2001036452A2 (en) 1999-11-18 2001-05-25 Epimmune Inc. Heteroclitic analogs of class i epitodes
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
US7297330B2 (en) * 2000-02-04 2007-11-20 Thomas Jefferson University Low dose haptenized tumor cell and tumor cell extract immunotherapy
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
NZ521715A (en) * 2000-04-28 2008-01-31 Mannkind Corp Method of identifying and producing antigen peptides and use thereof as vaccines
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
DE60238864D1 (de) * 2001-11-07 2011-02-17 Mankind Corp Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption
US20050221350A1 (en) 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
US9090673B2 (en) * 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
CA2592922A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
JP2008545180A (ja) * 2005-05-12 2008-12-11 メルク エンド カムパニー インコーポレーテッド Ｔ細胞エピトープの全自動選択システムおよび方法
EP1885393A4 (en) 2005-05-18 2011-03-02 Childrens Hosp & Res Ct Oak METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST CHLAMYDIA INFECTIONS
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
US20080107668A1 (en) * 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2008100598A2 (en) * 2007-02-15 2008-08-21 Mannkind Corporation A method for enhancing t cell response
CA2688061A1 (en) * 2007-05-23 2008-12-04 Mannkind Corporation Multicistronic vectors and methods for their design
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
AU2010310468A1 (en) 2009-10-23 2012-05-24 Mannkind Corporation Cancer immunotherapy and method of treatment
EP3294324A1 (en) 2015-05-13 2018-03-21 Agenus Inc. Vaccines for treatment and prevention of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU619458B2 (en) * 1987-01-30 1992-01-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte inhibition by hla peptides
IL92629A0 (en) * 1989-12-10 1990-08-31 Yeda Res & Dev Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases

Also Published As

Publication number Publication date
JPH06510850A (ja) 1994-12-01
AU1694392A (en) 1992-12-30
CA2103148C (en) 2004-07-20
US5747269A (en) 1998-05-05
JP2003176300A (ja) 2003-06-24
CA2471093A1 (en) 1992-11-26
EP0584136A1 (de) 1994-03-02
EP0584136B1 (de) 2000-02-02
CA2103148A1 (en) 1992-11-18
DE59209810D1 (de) 2000-03-09
ATE189527T1 (de) 2000-02-15
DK0584136T3 (da) 2000-05-22
JP3424752B2 (ja) 2003-07-07
WO1992021033A1 (de) 1992-11-26
DE4143467C2 (de) 1995-02-09

Similar Documents

Publication Publication Date Title
ES2145007T3 (es) Determinacion de motivos peptidicos en moleculas del mhc.
ES2109658T3 (es) Determinacion de motivos peptidicos en moleculas del mhc.
ES2121793T3 (es) Composiciones de uso local para la administracion transdermica de derivados profarmacos de morfina.
CO4410203A1 (es) Formulaciones de analogos de insulina
BR9811927A (pt) Dispositivo de liberação de agente benéfico propelido por gás que pode ser implantado
BR0014483A (pt) Dispositivo de injeção para uso único
ES2170801T3 (es) Composiciones para el cuidado capilar que contienen formamida n-vinil polimerica y metodos para tratar el cabello.
ES2000428T3 (es) Procedimiento para producir un medicamento para el tratamiento de la enfermedad de alzheimer, que contiene galantamina, y dispositivo medico correspondiente.
ES2168395T3 (es) Nueva formulacion antitrombotica, procedimiento para su preparacion y utilizacion de la misma.
ES2134277T3 (es) Producto de organo-aluminoxi y uso.
NO955361L (no) Organiske aerogeler
AR241103A1 (es) "dispositivo de rebajamiento del ala de una butaca anatomica envolvente para el vehiculo automotor o analogo, y butaca que comprende dicho dispositivo".
ES2166761T3 (es) Composiciones que liberan sustancias aromaticas topicas.
ES2144151T3 (es) Benzotiazepinas hipolipidemicas.
ES2143122T3 (es) Sulfonimidamidas sustituidas, procedimiento para su preparacion, su utilizacion como medicamento o agente de diagnostico, asi como medicamento que las contiene.
EP0600930A4 (en) DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASES.
AR023806A1 (es) Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas
ES2020032A6 (es) Procedimiento de obtencion de composiciones oftalmicas a base de ciclosporina.
ES2038650T3 (es) Procedimiento para preparar una composicion farmaceutica que comprende 3'-desoxitimidin-2'-eno-(3'-desoxi-2',3'-dideshidrotimidina) para tratar pacientes infectados con retrovirus.
ES2062100T3 (es) Empleo de acetil l-carnitina en el tratamiento terapeutico de cataratas y composiciones farmaceuticas utiles en este tratamiento.
ES2103493T3 (es) Uso de parathormona, de sus fragmentos biologicamente activos y de peptidos relacionados para el tratamiento del embarazo.
ES2082831T3 (es) Composicion para tratamiento de tejidos con propiedades suavizantes.
ES2172703T3 (es) Composiciones de fluoruro de perfluoro(alcoxiciclo alcano)carbonilo, y su uso.
ES2184880T3 (es) Asociacion hormonal estrogeno-progestageno, su procedimiento de preparacion y su utilizacion en medicamentos.
DK0737069T3 (da) Deuterede aktive stoffer til transdermal administrering

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 584136

Country of ref document: ES